MNKD (MannKind) Notes Receivable: $0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MNKD MannKind Corp MNKD
66 GF Score
Price $4.26
GF Value $7.40
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is MannKind Notes Receivable?

MannKind MNKD -3.07% 66 Notes Receivable is $0.0 Mil as of Jun. 2026. GuruFocus rates MNKD with a GF Score™ of 66/100 and a GF Value™ of $7.40 (Possible Value Trap). The stock has 8 warning signs investors should review.

MannKind's Notes Receivable for the quarter that ended in Jun. 2026 was $0.0 Mil.

MannKind Notes Receivable Historical Data

* Premium members only.

The historical data trend for MannKind's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MannKind Notes Receivable Chart

MannKind Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MannKind Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MNKD
66GF Score
MannKind Corp MNKD
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MannKind Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.0 Mil mean?
MannKind (MNKD) has a Notes Receivable of $0.0 Mil as of Jun. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on MannKind and its competitors.
Is MannKind's Notes Receivable too high?
MannKind's current Notes Receivable is $0.0 Mil. Overall, MannKind has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MannKind's Notes Receivable compare to ABSI and ORIC?
MannKind's Notes Receivable of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on MannKind and its competitors. MannKind's current Notes Receivable is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MannKind stock overvalued right now?
Based on GuruFocus' analysis, MannKind (MNKD) is currently considered Possible Value Trap. The stock's GF Value™ is $7.40, compared to a current price of $4.26 — trading 42.4% below its estimated fair value. The current Notes Receivable is $0.0 Mil. MannKind's overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For MannKind (MNKD), the current Notes Receivable is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MannKind (MNKD) Overvalued in 2026?

Based on GuruFocus' analysis, MannKind stock appears to be undervalued. The current stock price of $4.26 is trading 42.4% below its estimated GF Value™ of $7.40. GuruFocus considers MannKind to be Possible Value Trap.

Key valuation signals for MNKD:

  • Notes Receivable: $0.0 Mil
  • GF Value™: $7.40 vs. price of $4.26 (42.4% below fair value)
  • GF Score™: 66/100 with 8 warning signs

No single metric tells the full story. See the MNKD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MannKind Business Description

Other Exchanges NNFN:Germany
Address 1 Casper Street, Danbury, CT, USA, 06810
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
66GF Score

Get the complete analysis for MNKD

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.26
Price
$7.40
GF Value